S

Sanofi

Global pharma company; vaccines and R&D

Team Lead GRA Labeling Strategist

Full-TimeUpdated on 10/23/2026Deadline 10/31/26
No salary listed
Expert
Bachelor's, Master's, MD
Hyderabad, Telangana, India
HybridHybrid work in Hyderabad, India.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Knowledge of regulatory and labeling requirements in major markets for marketing authorization filings for new products and updates to marketed products, and of the purpose and objectives of Labeling Teams.
  • Strong knowledge of drug labeling requirements, including CCDS and EU and US guidance and regulations, and drug-device combinations.
  • Knowledge of US and EU regulations and the general international regulatory environment.
  • Ability to train and mentor junior Labeling team members on CCDS, EU, and US guidance, regulations, and strategy for implementing requirements in labeling text.
  • Ability to read and interpret Health Authority regulations and guidance and relevant company standard operating procedures.
  • Proven ability to lead labeling strategy connected to regulatory strategy.
  • Ability to lead matrix teams, manage up, negotiate, and build consensus on complex topics.
  • Ability to work autonomously on most topics, request feedback on highly complex topics, and provide oversight to direct reports.
  • Ability to lead multidisciplinary labeling working groups involving Global Regulatory Affairs, Global Pharmacovigilance, Global Medical Affairs, Legal, preclinical, and CMC stakeholders; propose labeling strategy; negotiate; resolve conflict; and build consensus.
  • Ability to support local countries as a global labeling subject matter expert during labeling negotiations and Health Authority discussions.
  • Ability to construct company responses to EU and US Health Authority questions related to labeling.
  • Knowledge of end-to-end labeling processes and interfaces between Regulatory, Medical Affairs, Pharmacovigilance, and Quality.
  • At least 10 years of relevant experience.
  • At least 3 years of people management experience for individuals in the managerial track.
  • Ability to build or learn scientific knowledge, such as statistics and disease-area knowledge, to improve agility across therapeutic areas.
  • Ability to search for public data on labeling elements and regulatory strategy using digital capabilities.
  • Ability to manage projects and people and document progress and outcomes for an assigned product and people portfolio.
  • Familiarity with labeling and document-management systems, such as Veeva Vault, EDMS, RIM systems, and text-verification or quality-control tools.
  • Required education as a physician, pharmacist, veterinarian, or holder of a bachelor's degree in Life Sciences.
  • Fluent business English.
  • Ability to communicate in writing and verbally, network, and coordinate discussions across company levels to resolve labeling topics.
  • Situational awareness, leadership, problem-solving, organizational, project-management, critical-thinking, analytical, and interpersonal skills; ability to manage multiple projects at short notice and work with associates and management domestically and internationally.
Responsibilities
  • Define and lead labeling strategy to create or update corporate labeling documents (CCDS, US, EU, and WHO) and corresponding patient leaflets for development projects and lifecycle-management or marketed products, including target product labeling for new indications, within regulatory submissions to obtain or update marketing authorizations and secure company or agency approval.
  • Coordinate labeling review and approval throughout the end-to-end labeling process, including preparing labeling components for regulatory submissions, participating in agency labeling negotiations leading to product approvals or updates, and releasing labeling for company use across development, marketed, and lifecycle-management products, including complex updates, line extensions, and new indications.
  • Support cross-functional teams as a labeling expert within GRAL, GRT, and GRA; contribute to global regulatory strategies and prepare labeling components for submission dossiers or Health Authority responses.
  • Chair multidisciplinary labeling working groups, present labeling proposals, develop consensus, and present proposals to the Labeling Governance Committee for internal approval.
  • Provide oversight for the team and assigned products, and strategic guidance on projects, including reviewing and validating labeling proposals as needed and informing management.
  • Ensure product and project coverage within the area of oversight, identify gaps, and propose solutions to management.
  • Serve on response teams for EU and US procedures, including complex matters such as European arbitrations or referrals, work sharing, PRAC questions, signal detection, labeling negotiations, and urgent safety restrictions, to maintain and ensure compliance of existing marketing authorizations.
  • Anticipate implementation hurdles, take action to minimize them, and inform management as needed.
  • Coordinate, create, and present labeling proposals to senior executive management through the Labeling Review Committee.
  • Assess relevant study reports, post-marketing pharmacovigilance data, and other scientific reports to support labeling proposals.
  • Perform labeling competitive and comparator analyses and provide expert insights.
  • Meet established submission timelines and quality standards for labeling deliverables.
  • Train and mentor students, VIEs, and apprentices on CCDS and EU and US guidance, regulations, and strategies for implementing them in labeling text.
  • Execute training plans, assess competency, and close individual training gaps through targeted development.
  • Lead and execute transversal projects that affect labeling across Sanofi portfolios or specific GBUs, and lead process-improvement workstreams.
Desired Qualifications
  • An advanced degree is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...